查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143809

可溶性鳥苷酸環化酶促效劑市場：全球市場預測，2026-2032年

Soluble Guanylate Cyclase Stimulators Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，可溶性鳥苷酸環化酶促效劑市場規模將達到 39.5 億美元，複合年成長率為 6.20%。

主要市場統計數據
基準年 2025 25.9億美元
預計年份：2026年 27億美元
預測年份 2032 39.5億美元
複合年成長率 (%) 6.20%

可溶性鳥苷酸環化酶促效劑：概述

可溶性鳥苷酸環化酶 (sGC) 激動劑是標靶治療，旨在透過提高可溶性鳥苷酸環化酶對內源性一氧化氮的敏感性來增強環磷酸鳥苷 (cGMP) 訊號傳導。在內源性一氧化氮供應不足的情況下，它們也可以直接刺激該酵素。其臨床意義主要體現在以一氧化氮-sGC-cGMP 訊號傳導受損為特徵的肺部和心血管疾病。該領域的發展受到多種因素的影響，包括每種藥物不同的作用機制、每種適應症的證據、安全性管理以及長期口服治療的實際需求。

臨床和監管方面的變化將改變可溶性鳥苷酸環化酶（sGC）興奮劑的作用

該領域的研究趨勢正從闡明作用機制轉向將這些療法定位為針對肺動脈高壓及相關心血管疾病的更具選擇性的治療方案。關鍵變化包括更重視患者表現型分析、與其他標靶路徑療法的聯合治療策略，以及對功能狀態、住院率、耐受性和用藥依從性等真實世界臨床情況的評估。監管和臨床實踐決策仍然依賴來自對照試驗的證據、具有臨床意義的終點指標、禁忌症的管理以及上市後安全性監測。這些因素驅動研發項目，這些項目明確界定了最有可能獲益的患者群體，並區分了其與現有標準治療的附加價值。

人工智慧在sGC刺激器的開發與維護上的應用

人工智慧可以透過改善臨床試驗受試者招募、識別具有臨床意義的患者亞群以及整合影像數據、實驗室數據、電子健康記錄和縱向結局數據，為可溶性鳥苷酸環化酶（sGC）促效劑生態系統提供支援。預測工具可能有助於檢測治療反應模式、不利事件風險和用藥依從性挑戰，但其效用取決於代表性的資料集、透明的檢驗以及臨床醫生的監督。在探索和開發階段，機器學習可以幫助闡明生物目標機制、在分子層面進行最佳化以及設計治療方案。在臨床實踐中，機器學習是診斷確認、藥物重新評估和個人化風險評估的補充，而非替代。

區域洞察：獲取途徑和證據環境的差異

在北美，肺動脈高壓專科診療與相對成熟的臨床試驗和藥物安全監測基礎設施相結合，但醫療服務的可近性仍受制於保險報銷、轉診途徑和預先核准。在歐洲，指引導向的診療、醫療技術評估和協調的監管標準備受重視，但其具體實施情況因國家而異。亞太地區臨床需求顯著，專科醫生數量也在不斷成長，但診斷、報銷和監管要求方面存在差異。拉丁美洲的特點是專科醫療中心和診斷工具的可近性存在差異，公共和私立醫療體係都會影響治療的可近性。在中東，集中式的三級醫療網路可以支援相關工作的實施，但其覆蓋範圍因地區而異。非洲在診斷能力、專科醫生數量和藥物可近性方面面臨更廣泛的限制，因此，加強醫療體系建設對於合理用藥至關重要。

小組洞察：政策協調與醫療保健系統現狀

東協市場反映了管理體制、收入水準和專科族群的多樣性，區域協調和本地證據有助於實現更一致的醫療服務取得。金磚國家擁有龐大且多元化的患者群體，但其報銷、生產和臨床研究環境各不相同，醫療服務的普及取決於各國的政策和基礎設施。歐盟受益於通用的法律規範，但定價和報銷仍主要由各成員國自行負責。七國集團成員國通常已建立完善的心血管疾病研究和專科醫療網路，但面臨經濟負擔和人口老化所帶來的壓力。海灣合作理事會成員國通常擁有強大的三級醫療體系和集中採購能力，但證據生成和醫療服務取得途徑因成員國而異。北約成員國的醫療體系各不相同，因此，加入北約遠不如各國的法規、報銷機制和臨床能力重要。

國家洞察：主要市場的不同優先事項

澳洲和加拿大依賴專科轉診網路和正式的報銷審核，但地理分散影響著醫療服務的可近性。巴西和墨西哥必須平衡都市區三級醫療體系與全國診斷體系和醫療保險覆蓋範圍不平衡的問題。中國正在循環系統和呼吸系統領域拓展專科醫療服務，同時也正在完善監管和報銷流程。印度面臨臨床專業知識日益成長以及經濟能力和醫療服務體系差異顯著的雙重挑戰。日本和韓國擁有先進的醫院基礎設施，但當地的實證醫學和定價機制對醫療服務的採納有顯著影響。法國、德國、義大利、西班牙和英國在成熟的歐洲臨床環境中運作，但在評估、採購和區域實施方面存在差異。俄羅斯的醫療服務可近性受到國內政策、醫療體系限制和國際供應因素的影響。在美國，專科醫療、保險公司要求和實證處方箋對治療路徑有重大影響。

領導者指南：共同建構證據、獲取途徑和安全保障

產業領導者應透過嚴謹的表現型分析和具有臨床意義的終點指標來界定最有價值的患者群體，而非僅依賴寬泛的市場定位。研發計畫應評估聯合療法與現有療法的療效，並收集不同研究中心和患者群體中患者報告的長期療效數據。准入策略應根據國家健保報銷體系進行調整，並以透明的衛生經濟學證據為支持。安全計畫應提供清晰的教育，內容涵蓋禁忌症、藥物交互作用、監測以及（如適用）懷孕相關限制。此外，隨著數位化和人工智慧工具的普及，各機構還應投資於診斷能力、專科醫生培訓、用藥依從性支援以及檢驗的數據基礎設施，以確保臨床治療決策的課責。

調查方法：對 sGC 興奮劑的現況進行基於證據的綜合分析。

本執行摘要對已確立的可溶性鳥苷酸環化酶激動劑的臨床和監管研究結果進行了結構化的定性回顧。評估內容包括作用機制、目標疾病領域、臨床開發重點、安全性和監測要求、醫療服務體系、區域進入條件以及政策背景。報告整合了基於監管體系、專科醫療機構、報銷機制和研究基礎設施等方面普遍存在的差異而得出的區域、群體和國家層面的具體觀察。本報告不包含任何市場估算、預測或公司特定聲明。在做出任何臨床、投資或政策決策之前，應根據現行指南、產品附加檔、監管決策和同儕審查的證據對報告內容進行檢驗。

結論：將 sGC 的生物學特性轉化為對患者永續的價值。

可溶性鳥苷酸環化酶激動劑因其獨特的藥理機制能夠解決中樞訊號傳導異常，在靶向心血管和肺血管治療中發揮至關重要的作用。未來的進展更取決於精準的病患選擇、持續的療效證據、安全的聯合治療、公平的用藥途徑以及與專科醫療體系的有效整合，而非僅僅依賴其作用機製本身。目前仍存在顯著的區域和國家差異，因此本地化實施至關重要。那些能夠將創新與嚴謹的實證醫學、負責任的安全管理以及健全的醫療體系相結合的領導者，將更有能力提升此類療法的實際應用價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：可溶性鳥苷酸環化酶促效劑市場：依產品類型分類

  • 品牌
  • 非專利的

第8章：可溶性鳥苷酸環化酶激動劑市場：依適應症分類

  • 慢性血栓栓塞性肺動脈高壓
  • 肺動脈高壓

第9章：可溶性鳥苷酸環化酶促效劑市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第10章：可溶性鳥苷酸環化酶促效劑市場：依最終用戶分類

  • 居家醫療
  • 醫院
  • 專科診所

第11章：可溶性鳥苷酸環化酶促效劑市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章：可溶性鳥苷酸環化酶促效劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：可溶性鳥苷酸環化酶促效劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AbbVie Inc
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Cyclerion Therapeutics, Inc
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Grunenthal GmbH
  • Ironwood Pharmaceuticals, Inc
  • Johnson & Johnson
  • Merck & Co., Inc
  • MSD Europe Inc
  • Novartis AG
  • NOXXON Pharma NV
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

第16章 主要專家

Product Code: MRR-9C4233EE7D98

The Soluble Guanylate Cyclase Stimulators Market is projected to grow by USD 3.95 billion at a CAGR of 6.20% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.59 billion
Estimated Year [2026] USD 2.70 billion
Forecast Year [2032] USD 3.95 billion
CAGR (%) 6.20%

Soluble Guanylate Cyclase Stimulators: Executive Overview

Soluble guanylate cyclase (sGC) stimulators are a targeted therapeutic class designed to enhance cyclic guanosine monophosphate signaling by sensitizing soluble guanylate cyclase to endogenous nitric oxide and, in some settings, directly stimulating the enzyme when nitric oxide availability is limited. Their clinical relevance is tied primarily to pulmonary vascular and cardiovascular disorders characterized by impaired nitric oxide-sGC-cGMP signaling. The field is shaped by differentiated mechanisms of action, indication-specific evidence, safety management, and the practical requirements of long-term oral treatment.

Clinical and Regulatory Shifts Reshaping sGC Stimulators

The landscape is moving from proof of mechanism toward more selective treatment positioning across pulmonary hypertension and related cardiovascular conditions. Important shifts include greater emphasis on patient phenotyping, combination strategies with other pathway-directed therapies, and real-world assessment of functional status, hospitalization, tolerability, and adherence. Regulatory and clinical practice decisions continue to depend on controlled-trial evidence, clinically meaningful endpoints, contraindication management, and post-authorization safety monitoring. These factors favor development programs that clearly define the population most likely to benefit and distinguish incremental value from existing standards of care.

Artificial Intelligence Across sGC Stimulator Development and Care

Artificial intelligence can support the sGC stimulator ecosystem by improving trial recruitment, identifying clinically relevant patient subgroups, and integrating imaging, laboratory, electronic health record, and longitudinal outcome data. Predictive tools may help detect treatment-response patterns, adverse-event risk, and adherence challenges, but their utility depends on representative datasets, transparent validation, and clinician oversight. In discovery and development, machine learning can assist target biology, molecular optimization, and protocol design; in practice, it should complement-not replace-diagnostic confirmation, medication review, and individualized risk assessment.

Regional Insights: Divergent Access and Evidence Environments

North America combines specialized pulmonary-hypertension care with comparatively mature clinical-trial and pharmacovigilance infrastructure, while access remains influenced by reimbursement, referral pathways, and prior authorization. Europe places strong emphasis on guideline-based care, health-technology assessment, and coordinated regulatory standards, although implementation differs among countries. Asia-Pacific presents substantial clinical need and expanding specialist capacity, alongside variation in diagnosis, reimbursement, and regulatory requirements. Latin America is characterized by uneven access to specialty centers and diagnostics, with public and private systems shaping treatment availability. In the Middle East, concentrated tertiary-care networks can support adoption but coverage varies by jurisdiction. Africa faces wider constraints in diagnostic capacity, specialist availability, and medicine access, making health-system strengthening central to responsible use.

Group Insights: Policy Alignment and Health-System Readiness

ASEAN markets reflect diverse regulatory systems, income levels, and specialist capacity, so regional harmonization and local evidence can facilitate more consistent access. BRICS countries combine large and varied patient populations with differing reimbursement, manufacturing, and clinical-research environments; implementation therefore depends on national policy and infrastructure. The European Union benefits from shared regulatory structures, while pricing and reimbursement remain principally national responsibilities. G7 members generally have established cardiovascular research and specialty-care networks, but face affordability and aging-population pressures. GCC countries often possess strong tertiary-care capabilities and centralized procurement potential, while evidence generation and access pathways differ across members. NATO members span multiple health systems, making alliance membership less determinative than national regulation, reimbursement, and clinical capacity.

Country Insights: Distinct Priorities Across Major Markets

Australia and Canada rely on specialist referral networks and formal reimbursement assessment, with geographic dispersion affecting access. Brazil and Mexico must balance urban tertiary-care capability with uneven nationwide diagnosis and coverage. China is expanding specialty cardiovascular and pulmonary services while refining regulatory and reimbursement pathways. India combines growing clinical expertise with substantial variation in affordability and care delivery. Japan and South Korea have advanced hospital infrastructure, but local evidence and pricing processes strongly influence adoption. France, Germany, Italy, Spain, and the United Kingdom operate within mature European clinical environments, with differences in assessment, procurement, and regional implementation. Russia's access environment is shaped by domestic policy, healthcare-system constraints, and international supply considerations. In the United States, specialist care, payer requirements, and evidence-based prescribing materially influence treatment pathways.

Actions for Leaders: Build Evidence, Access, and Safety Together

Industry leaders should define the highest-value patient populations through rigorous phenotyping and clinically meaningful endpoints rather than broad positioning alone. Development plans should evaluate complementary use with established therapies, include diverse sites and populations, and capture patient-reported and long-term outcomes. Access strategies should be adapted to national reimbursement structures and supported by transparent health-economic evidence. Safety programs need clear education on contraindications, interactions, monitoring, and pregnancy-related restrictions where applicable. Organizations should also invest in diagnostic capacity, specialist education, adherence support, and validated data infrastructure so that treatment decisions remain clinically accountable as digital and AI-enabled tools expand.

Methodology: Evidence-Based Synthesis of the sGC Stimulator Landscape

This executive summary uses a structured qualitative review of established clinical and regulatory knowledge concerning soluble guanylate cyclase stimulators. The assessment considers mechanism of action, disease areas, clinical-development priorities, safety and monitoring requirements, healthcare delivery, regional access conditions, and policy context. Regional, group, and country observations are synthesized from generally recognized differences in regulatory systems, specialty-care capacity, reimbursement, and research infrastructure. No market estimates, market shares, forecasts, or company-specific claims are used. Interpretations should be validated against current guidelines, product labeling, regulatory decisions, and peer-reviewed evidence before informing clinical, investment, or policy decisions.

Conclusion: Translating sGC Biology Into Durable Patient Value

Soluble guanylate cyclase stimulators occupy an important position in targeted cardiovascular and pulmonary vascular therapy because they address a central signaling defect through a differentiated pharmacologic mechanism. Future progress will depend less on mechanism alone than on precise patient selection, durable outcome evidence, safe combination use, equitable access, and effective integration into specialist care. Regional and national variation will remain significant, making locally informed implementation essential. Leaders that connect innovation with rigorous evidence, responsible safety management, and health-system readiness will be best positioned to improve the real-world value of this therapeutic class.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Soluble Guanylate Cyclase Stimulators Market, by Product Type

  • 7.1. Introduction
  • 7.2. Branded
  • 7.3. Generic

8. Soluble Guanylate Cyclase Stimulators Market, by Indication

  • 8.1. Introduction
  • 8.2. Chronic Thromboembolic Pulmonary Hypertension
  • 8.3. Pulmonary Arterial Hypertension

9. Soluble Guanylate Cyclase Stimulators Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
    • 9.4.1. Chain Pharmacies
    • 9.4.2. Independent Pharmacies

10. Soluble Guanylate Cyclase Stimulators Market, by End User

  • 10.1. Introduction
  • 10.2. Home Care Settings
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Soluble Guanylate Cyclase Stimulators Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. Soluble Guanylate Cyclase Stimulators Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. Soluble Guanylate Cyclase Stimulators Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AbbVie Inc
  • 15.2. Astellas Pharma Inc
  • 15.3. AstraZeneca plc
  • 15.4. Bayer AG
  • 15.5. Bristol-Myers Squibb Company
  • 15.6. Cipla Limited
  • 15.7. Cyclerion Therapeutics, Inc
  • 15.8. Dr Reddy's Laboratories Ltd
  • 15.9. Eli Lilly and Company
  • 15.10. F. Hoffmann-La Roche AG
  • 15.11. GlaxoSmithKline plc
  • 15.12. Grunenthal GmbH
  • 15.13. Ironwood Pharmaceuticals, Inc
  • 15.14. Johnson & Johnson
  • 15.15. Merck & Co., Inc
  • 15.16. MSD Europe Inc
  • 15.17. Novartis AG
  • 15.18. NOXXON Pharma N.V
  • 15.19. Pfizer Inc
  • 15.20. Sanofi S.A
  • 15.21. Sun Pharmaceutical Industries Ltd
  • 15.22. Takeda Pharmaceutical Company Limited
  • 15.23. Teva Pharmaceutical Industries Ltd

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Soluble Guanylate Cyclase Stimulators Market, Years Considered for the Study
  • FIGURE 2. Global Soluble Guanylate Cyclase Stimulators Market, Research Design
  • FIGURE 3. Global Soluble Guanylate Cyclase Stimulators Market, Research Framework
  • FIGURE 4. Global Soluble Guanylate Cyclase Stimulators Market, Data Triangulation
  • FIGURE 5. Global Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 9. Global Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 11. Global Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global Soluble Guanylate Cyclase Stimulators Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global Soluble Guanylate Cyclase Stimulators Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Soluble Guanylate Cyclase Stimulators Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Soluble Guanylate Cyclase Stimulators Market Segmentation & Coverage
  • TABLE 2. Global Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Branded Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Branded Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Branded Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Generic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Generic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Generic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 11. Global Chronic Thromboembolic Pulmonary Hypertension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 12. Global Chronic Thromboembolic Pulmonary Hypertension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 13. Global Chronic Thromboembolic Pulmonary Hypertension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 14. Global Pulmonary Arterial Hypertension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 15. Global Pulmonary Arterial Hypertension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 16. Global Pulmonary Arterial Hypertension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 17. Global Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 18. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 19. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 20. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 21. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 22. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 23. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 24. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 25. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 26. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 27. Global Chain Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 28. Global Chain Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 29. Global Chain Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 30. Global Independent Pharmacies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 31. Global Independent Pharmacies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 32. Global Independent Pharmacies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 33. Global Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 34. Global Home Care Settings Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Home Care Settings Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Home Care Settings Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Asia-Pacific Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 45. Asia-Pacific Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 46. Asia-Pacific Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 47. Asia-Pacific Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 48. Asia-Pacific Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 49. Asia-Pacific Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 50. North America Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. North America Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 52. North America Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 53. North America Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 54. North America Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 55. North America Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 56. Latin America Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Latin America Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 58. Latin America Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 59. Latin America Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 60. Latin America Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 61. Latin America Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 62. Europe Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Europe Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 64. Europe Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 65. Europe Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 66. Europe Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 67. Europe Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 68. Middle East Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Middle East Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 70. Middle East Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 71. Middle East Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 72. Middle East Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 73. Middle East Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 74. Africa Soluble Guanylate Cyclase Stimulators Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 75. Africa Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 76. Africa Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 77. Africa Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 78. Africa Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 79. Africa Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 80. Global Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. ASEAN Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 82. ASEAN Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 83. ASEAN Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 84. ASEAN Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 85. ASEAN Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 86. ASEAN Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 87. GCC Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 88. GCC Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 89. GCC Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 90. GCC Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 91. GCC Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 92. GCC Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 93. European Union Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. European Union Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 95. European Union Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 96. European Union Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 97. European Union Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 98. European Union Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 99. BRICS Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. BRICS Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 101. BRICS Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 102. BRICS Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 103. BRICS Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 104. BRICS Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 105. G7 Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. G7 Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 107. G7 Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 108. G7 Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 109. G7 Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 110. G7 Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 111. NATO Soluble Guanylate Cyclase Stimulators Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. NATO Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 113. NATO Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 114. NATO Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 115. NATO Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 116. NATO Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 117. Global Soluble Guanylate Cyclase Stimulators Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 118. United States Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 119. United States Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 120. United States Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 121. United States Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 122. United States Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 123. United States Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 124. Canada Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 125. Canada Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 126. Canada Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 127. Canada Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 128. Canada Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 129. Canada Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 130. Mexico Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 131. Mexico Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 132. Mexico Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 133. Mexico Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. Mexico Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 135. Mexico Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. Brazil Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 137. Brazil Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 138. Brazil Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 139. Brazil Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 140. Brazil Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 141. Brazil Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 142. United Kingdom Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 143. United Kingdom Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 144. United Kingdom Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 145. United Kingdom Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 146. United Kingdom Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 147. United Kingdom Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 148. Germany Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 149. Germany Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 150. Germany Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 151. Germany Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 152. Germany Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 153. Germany Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 154. France Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 155. France Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 156. France Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 157. France Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. France Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 159. France Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 160. Russia Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 161. Russia Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 162. Russia Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 163. Russia Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 164. Russia Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 165. Russia Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 166. Italy Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 167. Italy Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 168. Italy Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 169. Italy Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 170. Italy Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 171. Italy Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Spain Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 173. Spain Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 174. Spain Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 175. Spain Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 176. Spain Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 177. Spain Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 178. China Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 179. China Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 180. China Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 181. China Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 182. China Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 183. China Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 184. India Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 185. India Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 186. India Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 187. India Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 188. India Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 189. India Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 190. Japan Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 191. Japan Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 192. Japan Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 193. Japan Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 194. Japan Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 195. Japan Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 196. Australia Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 197. Australia Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 198. Australia Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 199. Australia Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 200. Australia Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 201. Australia Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 202. South Korea Soluble Guanylate Cyclase Stimulators Market Size, 2017-2032 (USD Million)
  • TABLE 203. South Korea Soluble Guanylate Cyclase Stimulators Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 204. South Korea Soluble Guanylate Cyclase Stimulators Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 205. South Korea Soluble Guanylate Cyclase Stimulators Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 206. South Korea Soluble Guanylate Cyclase Stimulators Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
  • TABLE 207. South Korea Soluble Guanylate Cyclase Stimulators Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 208. Global Soluble Guanylate Cyclase Stimulators Market Share, by Key Player, 2025
  • TABLE 209. Global Soluble Guanylate Cyclase Stimulators Market, Key Experts